Alkermes to Participate in Two Upcoming Investor Conferences
Alkermes to Participate in Two Upcoming Investor Conferences
DUBLIN, May 29, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in fireside chat presentations at two upcoming investor conferences.
2024年5月29日,都柏林/美通社——Alkermes plc(納斯達克:阿爾凱默斯)今天宣佈,管理層將參加兩場即將舉行的投資者會議上的爐邊聊天演講。
Jefferies Healthcare Conference
Date/Time: Thursday, June 6, 2024 at 1:30 p.m. EDT (6:30 p.m. BST)
傑富瑞醫療保健會議
日期/時間:2024年6月6日,美國東部時間下午1:30(英國夏令時晚上6:30)
Goldman Sachs 45th Annual Global Healthcare Conference
Date/Time: Tuesday, June 11, 2024 at 10:40 a.m. EDT (3:40 p.m. BST)
高盛th年度全球醫療保健會議
日期/時間:2024年6月11日,美國東部時間上午10:40(英國夏令時下午3:40)
The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.
可在投資者選項卡下訪問直播網絡廣播,將保存14天。www.alkermes.com 將保存14天的直播網絡廣播可在投資者選項卡下訪問。
About Alkermes plc
Alkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of neuroscience. The company has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of clinical and preclinical candidates in development for neurological disorders, including narcolepsy. Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
關於阿爾凱默斯公
阿爾凱默斯公是一家全球神經科學生物製藥公司,致力於開發創新型藥物。該公司擁有一系列專有的商業產品,用於治療酒精依賴、阿片類依賴、精神分裂症和I型躁狂症,以及發展中的臨床前和臨床階段的候選藥物,用於治療神經系統疾病,包括納休症。阿爾凱默斯公總部位於愛爾蘭,在馬薩諸塞州擁有一家企業辦事處和研發中心,在俄亥俄州擁有一家制造工廠。有關更多信息,請訪問阿爾凱默斯公司的網站 www.alkermes.com .
Alkermes Contact:
Jamie Constantine
Investor Relations
+1 781 873 2402
阿爾凱默斯聯繫人:
傑米·康斯坦丁
投資者關係
+1 781 873 2402
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-to-participate-in-two-upcoming-investor-conferences-302158279.html
SOURCE Alkermes plc
來源 阿爾凱默斯有限公司